GPT and gastroenteritis: The incidence of increased ALT/AST, gastroenteritis, and rash between the Sintilimab group compared with the Pembrolizumab group were 28.3% (15/53) versus 40.0% (8/20), 3.8% (2/53) versus 15.0% (3/20), 3.8% (2/53) versus 5.0% (1/20), respectively.